CD63 and COVID-19: The relationship between CD63, CD32, C3aR and clinical disease indicated by ferritin levels and organ damage biomarkers in the blood suggested that the platelet activation potential of plasma from COVID-19 patients might provide additional insights into disease pathogenesis.